Puerperal febrile morbidity associated with the reverse transcriptase inhibitor stavudine.
We report a case of postpartum drug fever associated with stavudine, a new reverse transcriptase inhibitor. A human immunodeficiency virus (HIV)-infected patient experienced fevers to 102.6 degrees F following vaginal delivery and bilateral partial salpingectomy. When history, physical, laboratory, and radiographic evaluations did not reveal a source of infection, discontinuation of the stavudine led to rapid defervescence within 28 hours. Stavudine-associated fever may be a cause of puerperal febrile morbidity in the HIV-seropositive patient without a source of infection.
Wax
J R
JR
Department of Obstetrics and Gynecology, Naval Medical Center, Portsmouth, Virginia 23708, USA.
Mueller
S
S
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006679:HIV Seropositivity / Q000188:drug therapy; D006801:Humans; D011247:Pregnancy; D011644:Puerperal Disorders; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine